文献速递免疫规划

恒河猴DNA-MVA-蛋白疫苗接种诱导黏膜相关淋巴结HIV特异性免疫及功能性抗体

DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies.
PubMed 文献 · Vaccine · 2017-01-06

研究对先前接受DNA-C与MVA-C疫苗方案的恒河猴,在3.5年后再次接种MVA-C、HIV-1 C亚型包膜蛋白gp140Env/MF59及两者同时加强,单次MVA-C再接种诱导全部动物T细胞应答,同时加强在6/7动物多个黏膜相关淋巴结诱导HIV特异性细胞应答,两种方案均诱导高滴度Env特异性抗体、ADCC活性及Tier 1病毒中和。

要点

  • 单次MVA-C再接种诱导全部动物T细胞应答,4/7动物应答>1000 SFU/10^6 PBMC。
  • MVA-C与Env/MF59同时加强在6/7动物多个黏膜相关淋巴结诱导HIV特异性细胞应答。
  • 两种方案均诱导高滴度Env特异性抗体、ADCC活性及Tier 1病毒中和。

核心结论

  • DNA和痘病毒载体疫苗联合HIV包膜蛋白疫苗可在血液和病毒入侵黏膜部位诱导HIV特异性免疫。

研究设计与样本

  • 研究对先前接受DNA-C和MVA-C疫苗方案的恒河猴,在3.5年后再次接种MVA-C,随后接种基于HIV-1 C亚型包膜、以MF59为佐剂的gp140Env/MF59蛋白疫苗,最后同时加强两种疫苗。

主要发现

  • 单次MVA-C再接种诱导全部动物T细胞应答,与先前峰值应答相似,4/7动物应答>1000 SFU/10^6 PBMC。
  • 与仅用Env/MF59疫苗相比,MVA-C与Env/MF59同时加强在6/7动物多个黏膜相关淋巴结诱导HIV特异性细胞应答,部分动物应答强度高。
  • 两种疫苗方案均诱导高滴度Env特异性抗体,具有ADCC活性,并中和Tier 1病毒及 modest Tier 2中和。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Successful future HIV vaccines are expected to generate an effective cellular and humoral response against the virus in both the peripheral blood and mucosal compartments. We previously reported the development of DNA-C and MVA-C vaccines based on HIV-1 subtype C and demonstrated their immunogenicity when given in a DNA prime-MVA boost combination in a nonhuman primate model. In the current study, rhesus macaques previously vaccinated with a DNA-C and MVA-C vaccine regimen were re-vaccinated 3.5years later with MVA-C followed by a protein vaccine based on HIV-1 subtype C envelope formulated with MF59 adjuvant (gp140Env/MF59), and finally a concurrent boost with both vaccines. A single MVA-C re-vaccination elicited T cell responses in all animals similar to previous peak responses, with 4/7 demonstrating responses >1000 SFU/106 PBMC. In contrast to an Env/MF59-only vaccine, concurrent boosting with MVA-C and Env/MF59 induced HIV-specific cellular responses in multiple mucosal associated lymph nodes in 6/7 animals, with high magnitude responses in some animals. Both vaccine regimens induced high titer Env-specific antibodies with ADCC activity, as well as neutralization of Tier 1 viruses and modest Tier 2 neutralization. These data demonstrate the feasibility of inducing HIV-specific immunity in the blood and mucosal sites of viral entry by means of DNA and poxvirus-vectored vaccines, in combination with a HIV envelope-based protein vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chege GK, Burgers WA, Müller TL, et al. DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. Vaccine. 2017. PMID: 28069361. doi:10.1016/j.vaccine.2016.12.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。